Histologically, PLAG–RP1 fusion is a useful specific marker for identifying CXPA, especially those of salivary gland origin.2, 3Prognosis is relatively favorable with 5-year overall and cancer-specific survival of 81.9%.4Signs and symptoms at presentation typically include rapid eyelid swelling, proptosis, pain, and vision change.5Treatment strategies involve surgical resection and adjuvant therapy as indicated by pathologic features. Here, RP1 is linked to cancer.